Akeso Inc. announced that ivonescimab, its novel therapy for EGFR-mutated non-squamous non-small cell lung cancer (nsq-NSCLC) following EGFR-TKI progression, received regulatory approval from the China National Medical Products Administration in May 2024. The drug was subsequently added to China's National Reimbursement Drug List (NRDL) in November 2024, ensuring broad patient access starting January 1, 2025. Additionally, Akeso's global partner, Summit Therapeutics, plans to submit a Biologics License Application (BLA) to the U.S. FDA in the fourth quarter of 2025 for the same indication.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN18891) on November 07, 2025, and is solely responsible for the information contained therein.